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Abstract
Background: Clinically significant premenstrual symptoms are common among young women. Premenstrual
syndrome (PMS) is characterized by emotional, behavioural and physical symptoms that consistently occur during
the luteal phase of the menstrual cycle. Premenstrual dysphoric disorder (PMDD) is a severe form of PMS.
Individual variation in stress responsiveness may be involved in the pathophysiology of premenstrual symptoms.
Preterm birth at very low birth weight (VLBW, < 1500g) has a multitude of consequences that extend to adult life,
including altered stress responsiveness which could affect the prevalence of premenstrual symptoms.
Methods: In this cohort study, we compared 75 VLBW women with 95 women born at term (mean age 22.5). We
used a standardized retrospective questionnaire assessing the presence and severity of a variety of symptoms
before and after menses. The symptom scores were used both as continuous and as dichotomized variables, with
cutoffs based on DSM-IV criteria for PMDD and ACOG criteria for PMS, except prospective daily ratings could not
be used. We used multiple linear and logistic regression to adjust for confounders.
Results: There was no difference in the continuous symptom score before menses (mean difference VLBW-term
-18.3%, 95% confidence interval -37.9 to 7.5%) or after menses. The prevalence of premenstrual symptoms causing
severe impairment to daily life was 13.3% for VLBW women and 14.7% for control women. For PMDD, it was 8.0%
and 4.2%, and for PMS, 12.0% and 11.6%, respectively. These differences were not statistically significant (p > 0.1).
Conclusion: Our findings suggest that the severity of premenstrual symptoms and the prevalence of PMDD and
PMS among young women born preterm at VLBW is not higher than among those born at term.
Background
It is now widely accepted that several common adult
diseases have their origins during the fetal period and
infancy. Although there is some heterogeneity between
studies, adults born with low birth weight show
increased risk of cardiovascular disease [1,2], type 2 dia-
betes [3] and depression [4]. Recent studies by us [5,6]
and others [7-9] suggest particularly high levels of risk
factors for these disorders in young adults born preterm
at very low birth weight (VLBW, < 1500g).
Mechanisms that link early life events with adult dis-
ease remain poorly known. Early life programming of
endocrine and other physiological responses to stress
may have an important role to play [10]. There is emer-
ging evidence that preterm birth may affect stress
responsiveness in later life, in particular the function of
the hypothalamic-pituitary-adrenal (HPA) axis [10-12].
Up to 30% of women of reproductive age report pre-
menstrual symptoms severe enough to warrant diagnosis
of premenstrual syndrome (PMS) [13,14]. PMS is char-
acterized by cyclic and recurrent emotional, behavioural
and / or physical symptoms which occur during the late
luteal phase, remit within days of menses and are asso-
ciated with suffering and impairment premestrually [14].
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Premenstrual dysphoric disorder (PMDD) is a severe
form of PMS characterized by mood, behavioural and
cognitive complaints which seriously interfere with rela-
tionships, social activities and work. The estimated pre-
valence of PMDD is 3-8% [15]. The burden of PMDD
during the late luteal phase may reach the same level as
that of major dysphoric disorders.
Premenstrual disorders and symptoms are complex
phenomena which despite decades of research remain
poorly understood. Hormonal systems, in particular the
HPA axis, are believed to be involved [16-18], and the
prevailing view is that women with PMS are more sensi-
tive to essentially normal hormonal swifts. Important
determinants predicting how a woman will experience
premenstrual symptoms are also believed to include indi-
vidual differences in response to stress and adverse
events earlier in life [19,20]. While lifecourse studies have
thus far focused on events such as sexual abuse [21],
adverse events could as well be biological and occur early
in life: infants born preterm at VLBW experience after
birth a period of immaturity-associated illness charac-
terised by inadequate nutrition, impaired growth and
deprivation from normal parental attachment, and the
consequences of this period on hormonal function and
stress responsiveness extend to adult life. With this back-
ground, we hypothesized that young adult women born
at very low birth weight have a higher degree of pre-
menstrual symptoms than their peers born at term.
Methods
Participants
The participants were a subgroup of the Helsinki Study
of Very Low Birth Weight Adults, which has been
described in detail [5,6]. Briefly, the original study
cohort comprised 335 consecutive VLBW (< 1500g)
infants (of whom 178 were women) who were born
between January 1978 and December 1985 and who
were discharged alive from the neonatal intensive care
unit of Children’s Hospital at the Helsinki University
Central Hospital in Finland. For each VLBW survivor,
the next term born (gestational age > 37 weeks) single-
ton infant of the same sex, and not small for gestational
age (SGA, birth weight < -2SD) was selected to act as
control (n = 367, of whom 201 women). We invited 255
VLBW (139 women) and 314 term (169 women) partici-
pants who lived in the greater Helsinki area to a clinical
examination, and 166 (95 women, 68% of those invited)
and 172 (103 women, 61%) agreed to participate.
The follow-up study was conducted between April
2004 and June 2005. In June 2004, the questionnaire for
menstrually related disorders (described below) was
included in the protocol of each participating woman
who was not pregnant or lactating. Altogether 86
VLBW women and 101 women born at term completed
the retrospective questionnaire. For the final analysis, we
excluded 17 participants (11 VLBW) who reported hav-
ing received treatment for one or more major mental
disorder in the past three months (Table 1). The exclu-
sion was done because comorbid mental disorders could
impact the report of premenstrual symptoms [14]. The
final analysis thus included 75 preterm born VLBW par-
ticipants and 95 controls.
Procedures
We used a validated, widely used questionnaire to assess
self-reports of Menstrually-Related Disorders [22]. The
assessment retrospectively enquires symptoms during the
last three menstrual cycles, for each cycle during the
week before menses (premenstrual period) and the week
after menses. The 21 symptom items concern depressive
symptoms, irritability, affective lability, anxiety, change in
sleep, change in appetite (e.g. food cravings), decreased
interest in activities, difficulty concentrating, feeling out
of control or overwhelmed, lack of energy and physical
symptoms such as breast tenderness and swelling.
The participant was asked to score the severity of each
symptom from 1 to 5 (1 = minimal and 5 = extremely
severe). As continuous outcome variables we used the
sum of these scores before and after menses, plus the
difference of these scores. In addition, the questionnaire
includes three questions of the effect and burden of
these symptoms to work, social relationships and daily
activity, which were assessed separately.
As dichotomous outcomes, we used a) the score for
each individual question dichotomized at 3 or more to
indicate significant severe symptoms; b) whether the par-
ticipant fulfils the DSM-IV-based criteria of PMDD [23];
c) whether she fulfils the ACOG (American College of
Obstetricians and Gynecologists) [24] criteria for PMS,
with the exception that we could not apply prospective
daily ratings within this protocol. DSM-IV PMDD cri-
teria presume a person to have at least five premenstrual
symptoms (including at least one major dysphoric symp-
tom: irritability, depressed mood, affective lability or
anxiety) which seriously interfere with work, social activ-
ities and relationships. In addition, we assessed the pro-
portion of women who reported at least one dysphoric
symptom, which substantially impacts their life during
the premenstrual period. ACOG PMS criteria require
that a person has at least one affective (depression, angry
outbursts, irritability, anxiety, confusion, social withdra-
wal) or somatic (breast tenderness, abdominal bloating,
headache, swelling of extremities) symptom premenstru-
ally during each of three prior menstrual cycles.
Measures
Birth weight, gestational age and other perinatal and
maternal data (smoking during pregnancy, preeclampsia)
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were collected from hospital records. The participants
completed a wide range of questionnaires concerning
their medical history, use of medications, current educa-
tional level, smoking and parental education (the highest
level of current education achieved by either parent,
categorized into four levels). Weight and height were
measured and body mass index (BMI) was calculated.
Questionnaires were completed in conjunction with a
clinical examination. The study protocol was approved
by the Ethics Committee for Children and Adolescents
Diseases and Psychiatry at Helsinki and Uusimaa Hospi-
tal District. Each participant gave a written informed
consent.
Data analytic strategy
The study was powered with regard to differences in
symptom score as continuous variables. With 80%
power and alpha level of 0.05, 75 VLBW and 95 control









Birth weight, g 1125 (232) 3569 (474) < 0.0001
Gestational age, wk 29.4 (2.4) 40.3 (1.1) < 0.0001
Standard deviation score for birth weight -1.35 (1.60) 0.08 (1.04) < 0.0001
SGAb, n (%) 21 (24.4%) 0 < 0.0001
Maternal preeclampsiac, n (%) 19 (22.0%) 6 (5.9%) 0.001
Twin, n (%) 13 (15.1%) 0 < 0.0001
Triplet, n (%) 4 (4.7%) 0 < 0.0001
Parental
Maternal smoking during pregnancy, n (%) 15 (17.4%) 13 (12.9%) 0.4
Highest education of either parentd, n (%) 0.2
Elementary 12 (14.0%) 9 (8.9%)
High school 20 (23.3%) 16 (15.8%)
Intermediate 32 (37.2%) 36 (35.6%)
University 22 (25.6%) 39 (38.6%)
Current
Age, y 22.4 (2.1) 22.6 (2.3) 0.5
Height, cm 162.0 (7.6) 165.8 (13.5) 0.02
Weight, kg 58.3 (11.8) 63.8 (10.9) 0.001
BMI, kg/m2 22.1 (3.7) 22.7 (3.7) 0.2
Daily smoking, n (%) 19 (22.1%) 30 (29.7%) 0.2
Menarche, y 12.7 (1.5) 12.4 (1.4) 0.1
Regular menstrual cyclee, n (%) 51 (65.4%) 60 (65.9%) 0.9
Duration of menorrheaf, d 5.7 (2.8) 5.1 (1.8) 0.07
Hormonal contraception, n (%) 42 (48.8%) 56 (55.4%) 0.4
Contraceptive pills 37 (43.0%) 48 (47.5%)
Hormone releasing intrauterine device 2 (2.3%) 2 (2.0%)
Implantable contraceptive 0 1 (1.0%)
Other or unknown type of hormonal contraception 3 (3.5%) 5 (5.0%)
Treatment for mental disorders during previous three monthsg, n(%) 11 (12.8%) 6 (5.9%) 0.1
Depression 6 (7.0%) 5 (5.0%) 0.8
Anxiety or panic disorder 9 (10.5%) 5 (5.0%) 0.2
Eating disorder 3 (3.5%) 1 (1.0%) 0.2
Obsessive-compulsive disorder 0 1 (1.0%)
a) The t-test for continuous and chi-square test for categorical variables.
b) Small for gestational age, birth weight < -2 SD.
c) Data missing for one term participant.
d) Data missing for one term participant.
e) Menstrual cycle is regular when its duration is 21 to 35 days [22]. Data missing for 8 VLBW and 10 term participants.
f) Duration of last bleeding. Data missing for 7 VLBW and 5 term participants.
g) These participants were excluded from analysis of premenstrual symptoms.
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participants allow us to detect or exclude a 0.44 SD dif-
ference. With 90% power and alpha 0.01, the corre-
sponding difference is 0.60 SD. A total symptom score
was calculated as the sum of the score for each specific
symptom, with separate scores before and after menses.
The total score after menses was subtracted from the
total score before menses to evaluate the difference
between the premenstrual period and time after men-
struation. These scores were used as outcomes (with the
total scores log-transformed to attain normality)
together with the dichotomous outcome variables, calcu-
lated as described in the Procedures section. Differences
between VLBW young women and term controls were
examined by Student’s t-test for continuous variables,
Pearson’s chi square test for dichotomous variables and
multiple linear and logistic regressions to adjust for the
following covariates: age, parental education, BMI, the
current use of hormonal contraception, own current
smoking and maternal smoking during pregnancy. Com-
parisons of participating women with nonparticipants
regarding the duration of mechanical ventilation, the
duration of oxygen administration and age at discharge
were analyzed by means of the Mann-Whitney U test.
Results
Gestational age of prematurely born VLBW participants
ranged from 25.0 to 35.6 weeks and birth weights from
620 to 1490 g. The control participants’ gestational ages
ranged from 37.0 to 42.9 weeks and birth weights from
2560 to 4900 g. 24.4% of VLBW participants were born
small for gestational age. The prevalence of maternal
preeclampsia was 22.0% in the VLBW group and 5.9%
in the control group (p = 0.001). 19.8% of VLBW parti-
cipants were born from multiple pregnancies. At exami-
nation, the VLBW women were shorter (p = 0.02) and
lighter (p = 0.001) than those born at term, but the
groups were similar regarding the other baseline charac-
teristics (Table 1).
Table 2 shows mean scores of premenstrual symp-
toms, the prevalences of premenstrual syndrome and
premenstrual dysphoric disorder and each of its symp-
toms in study groups. In both groups the total sum
scores before menses (VLBW: geometric mean 9.9; con-
trols: 12.5) were higher than sum scores after menses
(VLBW: 3.4; controls: 4.3). The difference in the sum
score before and after menses was on average 7.6 for
the VLBW group and 8.1 for the control group. There
were no statistically significant differences between the
groups.
The prevalence of PMDD was 8.0% in the VLBW
group and 4.2% in the controls, and the prevalence of
PMS was 12.0% in the VLBW group and 11.6% in the
controls. The most prevalent symptoms in both groups
were affective lability, tension or anxiety, irritability and
various physical symptoms. In addition, 9.3% of VLBW
and 9.5% of term born participants reported at least one
dysphoric symptom which substantially impacts their
life during the premenstrual period. 13.3% of VLBW
participants and 14.7% of controls reported that pre-
menstrual symptoms seriously interfere with functioning
at work, or with family and social relationships. As the
odds ratios in Table 2 demonstrate, none of these differ-
ences was statistically significant. We also compared the
prevalence of each symptom separately; again there were
no statistically significant differences.
To assess possible associations with perinatal and neo-
natal conditions, we performed a range of analyses
within the VLBW group. We compared VLBW women
born SGA with VLBW women born AGA (appropriate
for gestational age); those exposed to maternal pree-
clampsia with those not exposed; and those who devel-
oped bronchopulmonary dysplasia with those who did
not. There were no differences in the total symptom
scores and in the prevalence of PMDD or PMS. Neither
were these outcomes associated with the duration of
mechanical ventilation, the duration of oxygen adminis-
tration and age at discharge.
As compared with non-participating women (=
women who were invited to the clinical examination but
who did not complete the premenstrual symptoms ques-
tionnaire), women who participated in the present study
have similar baseline characteristics including means of
birth weight (SD), gestational age, the duration of
mechanical ventilation, the duration of oxygen adminis-
tration and age at discharge; and prevalences of SGA,
maternal preeclampsia, bronchopulmonary dysplasia and
cerebral palsy diagnosed at 15 months of age (p values >
0.089).
As in our previous publications based on the same
cohort [5,6], we reanalyzed the data after the exclusion
of 10 participants with cerebral palsy (n = 8) or blind-
ness (n = 2). The results were similar. An additional rea-
nalysis was made after including the 17 participants who
had originally been excluded because of a comorbid
mental disorder. Again, the results were little changed.
Discussion
We hypothesized that young adult women born at
VLBW have a higher degree of premenstrual symptoms
than their peers born at term. Although we used a
detailed and widely used symptoms score questionnaire
[22] which is intended to detect even subtle differences
below the threshold of a clinically defined disorder, we
could find no differences between the VLBW and con-
trol women by any applied analytical method with or
without adjustment for covariates such as body size,
socio-economic status, smoking and use of hormonal
contraception. Although our study was not powered to
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detect small differences in clinical disorders, the preva-
lences of PMDD (8.0% in the VLBW and 4.2% in the
control group) and PMS (12.0% in VLBW, 11.6% in con-
trols) were consistent with previous reports [15,17] and
any substantial excess of these disorders in adult women
born at VLBW is unlikely.
Premenstrual symptoms and syndromes may be clini-
cally relevant and cause serious impairment even when
DSM-IV criteria are not met [15]. These symptoms
cause severe impairment in work, social activities and
relationships among a significant group of young
women. In the current study, the percentages of women
reporting impairment were 13.3% in the VLBW group
and 14.7% in the control group. This is in accordance
with estimated earlier percentages which have varied
between 13-18% [15].
With the exception a few studies focusing upon HPA
axis, there are little published data on the effect of pre-
term birth on hormonal axes including the hypothala-
mic-pituitary-gonadal (HPG) axis. The little data that
exist suggest that both girls and boys born at VLBW
have an earlier age at pubertal growth spurt than those
born at term [25]. Contrary to this, large register studies
suggest lower rates of reproduction [26,27] in women
and men born severely preterm. This may, however, be
due to personality traits leading to delays of starting
romantic relationships [28] rather than differences in
gonadal endocrine function which to our knowledge has
not been studied.
As to the individual differences in physiological stress
responsiveness, most studies have focused on the HPA
axis, but published results are not consistent. In a study
of 36 participants aged 8-14 years, Buske-Kirschbaum et
al. (2007) reported higher morning cortisol levels in for-
mer preterm children but found no difference in HPA
axis response to psychosocial stress. Preliminary findings
from a subgroup of women and men (53 VLBW and 42
term) from our study cohort suggest decreased HPA
axis responsiveness to stress [12]. Nevertheless, several
observations may support the role of normal variation
in HPA axis function in the pathophysiology of PMS.
For example, cortisol levels before menstruation were













Total score before menses 9.9a 12.5a -19.4% (-38.2 to 5.0%) -18.3% (-37.9 to 7.5%)
Total score after menses 3.4a 4.3a -17.7% (-41.8 to 16.3%) -14.7% (-40.5 to 22.5%)
Difference between total score before and after menses 7.6 8.1 -0.56 (-2.96 to 1.85) -0.71 (-3.24 to 1.83)
N (%) N (%) Odds ratio (95% CI)b Odds ratio (95% CI)c
PMDDd (DSM-IV) 6 (8.0) 4 (4.2) 1.97 (0.53 to 7.25) 1.82 (0.47 to 7.07)
PMDD symptomse 7 (9.3) 9 (9.5) 0.97 (0.34 to 2.76) 0.99 (0.33 to 2.93)
PMS (ACOG)f 9 (12.0) 11 (11.6) 1.03 (0.40 to 2.65) 1.00 (0.37 to 2.67)
PMS symptoms seriously interfere with work, social activities, relationships 10 (13.3) 14 (14.7) 0.88 (0.37 to 2.12) 0.89 (0.35 to 2.23)
Presence of each premenstrual symptom before menses
Depressed mood or hopelessness 8 (10.7) 4 (4.2) 2.71 (0.78 to 9.39) 2.24 (0.61 to 8.27)
Tension or anxiety 16 (21.3) 24 (25.3) 0.80 (0.39 to 1.64) 0.86 (0.40 to 1.87)
Affective lability 16 (21.3) 27 (28.4) 0.68 (0.33 to 1.39) 0.56 (0.26 to 1.19)
Irritability 13 (17.3) 24 (25.3) 0.62 (0.29 to 1.32) 0.61 (0.28 to 1.36)
Decrease interest in activities 6 (8.0) 5 (5.3) 1.56 (0.45 to 5.43) 1.51 (0.41 to 5.53)
Difficulty concentrating 6 (8.0) 5 (5.3) 1.57 (0.45 to 5.47) 1.59 (0.43 to 5.84)
Lack of energy 7 (9.3) 11 (11.6) 0.77 (0.28 to 2.10) 0.82 (0.29 to 2.34)
Change in appetite, e.g., food cravings 17 (22.7) 16 (16.8) 1.44 (0.67 to 3.09) 1.34 (0.60 to 2.99)
Change in sleep 8 (10.7) 9 (9.5) 1.13 (0.41 to 3.10) 1.00 (0.35 to 2.91)
Feeling out of control or overwhelmed 3 (4.0) 5 (5.3) 0.75 (0.17 to 3.24) 0.90 (0.19 to 4.23)
Other physical symptoms, e.g., breast tenderness,
bloating
20 (26.7) 32 (33.7) 0.72 (0.37 to 1.41) 0.68 (0.34 to 1.38)
a) Geometric mean.
b) Adjusted for age.
c) Adjusted for age, parental education, body mass index, current use of hormonal contraception, own current smoking and maternal smoking during pregnancy.
d) The prevalence of PMDD (premenstrual dysphoric disorder) based on DSM-IV (Diagnostic and Statistical Manual of Mental Disorders) criteria.
e) A person has premenstrually at least one of the following symptoms: depressed mood or hopelessness, tension or anxiety, affective lability or irritability, and
the symptoms seriously interfere with work, social activities or relationships and work.
f) The prevalence of PMS (premenstrual syndrome) based on ACOG (American College of Obstetricians and Gynecologists) criteria.
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lower in women who suffer from depressive symptoms
premenstrually [16]. In another study women with PMS
failed to show the normal increased HPA axis response
to exercise during the luteal phase and showed an
abnormal reaction of HPA axis to progesterone [18].
Our findings suggest that differences in hormonal func-
tions and physiological stress responsiveness between
women born at VLBW and those born at term, if they
exist, are not reflected in the prevalence of reported pre-
menstrual symptoms.
The main limitations of the study were the relatively
small study population, resulting in limited power espe-
cially in sub-group analyses. However, it is of note that
our sample size was larger than in most previous endo-
crine- and stress-related studies in people born preterm
[11,12]. Moreover, as prospective daily ratings were not
possible to realize, we obtained a retrospective report of
the most recent 3 menstrual cycles. Retrospective self-
report is not as reliable a method to reflect daily symp-
tom experience as are prospective daily ratings, which
also are the standard requirement for the accurate diag-
nosis of PMS or PMDD [29]. Therefore our finding of
no difference in the prevalence of reported PMDD and
PMS should be treated with caution.
Conclusions
In conclusion, premenstrual symptoms are common and
cause significant impairment in the daily life of many
young women. However, women born at VLBW seem
not to suffer from premenstrual symptoms more than
their peers born at term.
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